Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

2.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Announces Resignation of Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Present at The Microcap Conference 2025
Via ACCESSWIRE
News headline image
IPA to Present at The Microcap Conference 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
News headline image
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.